Luvixasertib is under clinical development by Treadwell Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Luvixasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Luvixasertib overview
luvixasertib (CFI-402257) is under development for the treatment of advanced solid tumors, colorectal cancer; endometrial cancer; hepatocellular carcinoma; leiomyosarcoma; pancreatic Cancer; sarcomas, and advanced or metastatic ER positive/Her2 negative breast cancer. The drug candidate is administered through oral route in the form of capsule. It belongs to pyrazolo-pyrimidines class. The drug candidate acts by targeting tyrosine threonine (TTK/MPS1) protein kinase.
It was also under development for the treatment of castrate refractory prostate cancer and lung cancer.
Treadwell Therapeutics overview
Treadwell Therapeutics is a clinical-stage biotechnology company that develops novel therapeutics for highly aggressive cancers. The company’s pipeline products comprise small cell therapeutic products, biologic therapy and T-cell receptor (TCR) based cell therapy products. Its pipeline includes CFI-400945 for acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, breast cancer, prostate cancer and solid tumors; CFI-402257 targets 2L ER+ breast cancer, solid tumors and breast cancer; CFI-402411 treat solid tumors; and TCR-based Cell therapy and biologic for tick-borne diseases. The company operates in the US, Canada and Hong Kong. Treadwell Therapeutics is headquartered in New York, the US.
For a complete picture of Luvixasertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
